Genomics research is the key to personalised medicine. In genomics, researchers study what it is about an individual’s genetic interactions and environment that can change the way their unique combination of genes influences a particular disease, and their response to a type and dose of medicine or other therapy.
Dr Shalin Naik is one of the researchers who works with the DROP-seq.
“Traditionally, researchers have been restricted to studying biological systems by looking at aggregated samples of cells,” he said. The DROP-seq will change that by allowing researchers to look at single cells to learn how they influence the way we respond to therapies.
“Traditionally, researchers have been restricted to studying biological systems by looking at aggregated samples of cells.”
Institute director Professor Doug Hilton welcomed the arrival of DROP-seq and its potential applications in a broad range of disease and research fields. “Implementation of this technology will be a major boost to single cell genomics research in Australia,” he said.
With the advent of personalised medicine, this research presents important opportunities for all Australians to get the sorts of therapies that are best suited to them and their illness.